# A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

> **NCT07204418** · PHASE1 · RECRUITING · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 56 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Xanomeline/ Trospium Chloride

## Key facts

- **NCT ID:** NCT07204418
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-13
- **Primary completion:** 2026-12-03
- **Final completion:** 2026-12-03
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204418, "A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07204418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*